IAMA Therapeutics
- Biotech or pharma, therapeutic R&D
IAMA Therapeutics is a clinical-stage biotechnology company developing novel therapies for neurodevelopmental and neuropsychiatric disorders by targeting chloride homeostasis, a key mechanism regulating neuronal excitability.
IAMA’s lead candidate, IAMA-6, is a first-in-class selective NKCC1 inhibitor.
The compound has successfully completed a Phase 1 clinical trial, demonstrating safety, tolerability, and target engagement in healthy volunteers.
Backed by a proprietary discovery platform focused on cation-chloride cotransporters (CCCs), IAMA is advancing a pipeline of new chemical entities aimed at delivering mechanism-based treatments for high unmet medical needs across epilepsy, autism spectrum disorders, and other central nervous system conditions.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}